Resistance to the BCL-XL degrader DT2216 in T-cell acute lymphoblastic leukemia is rare and correlates with decreased BCL-XL proteolysis is a research paper published in Cancer Chemotherapy and Pharmacology (2022). On theSindex it has a DataRank of 0.449. It has been cited 19 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.449
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →Division of Cancer Epidemiology and Genetics, National Cancer Institute
Grant: CA242003
Division of Cancer Epidemiology and Genetics, National Cancer Institute
Grant: CA205224
Cancer Prevention and Research Institute of Texas
Grant: RP220269
NCI NIH HHS
Grant: R01 CA242003
NCI NIH HHS
Grant: R01 CA205224
National Institutes of Health
Grant: 5R01CA205224-07
EEPD1 Repair of Stressed Replication Forks
National Institutes of Health
Grant: 5R01CA242003-03
Use of BCL-xL Proteolysis targeting chimeras to treat pancreatic cancer
FWCI
1.18
Citation Percentile
0.8%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals